BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35730811)

  • 21. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.
    Zhang R; Huang M; Wang H; Wu S; Yao J; Ge Y; Lu Y; Hu Q
    Pathol Oncol Res; 2021; 27():597527. PubMed ID: 34257549
    [No Abstract]   [Full Text] [Related]  

  • 23. SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma.
    Chang Q; Xu Y; Wang J; Jing H; Rao L; Tang W; Zhang Z; Wu X
    Comput Math Methods Med; 2021; 2021():8556888. PubMed ID: 34819993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Diagnostic Biomarkers and Subtypes of Liver Hepatocellular Carcinoma by Multi-Omics Data Analysis.
    Ouyang X; Fan Q; Ling G; Shi Y; Hu F
    Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulated mH2A1 serves as an unfavorable prognostic indicator and promotes the progress of hepatocellular carcinoma (HCC).
    Yang G; Yao Y; Wu D; Guo H; Zhou S; Sun D; Guo X; Zheng T; Wang J; Zhang S; Wang Y; Song R; Ke S; Liu Y; Meng F; Liang Y; Lu Z; Liu L
    Life Sci; 2020 Dec; 263():118576. PubMed ID: 33058912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
    Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
    Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy.
    Fu Q; Yang F; Xiang T; Huai G; Yang X; Wei L; Yang H; Deng S
    Sci Rep; 2018 May; 8(1):7933. PubMed ID: 29785036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated bioinformatics analysis identified MTHFD1L as a potential biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
    Chen J; Yang J; Xu Q; Wang Z; Wu J; Pan L; Huang K; Wang C
    Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33605411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.
    Zhang YP; Bao ZW; Wu JB; Chen YH; Chen JR; Xie HY; Zhou L; Wu J; Zheng SS
    Technol Cancer Res Treat; 2020; 19():1533033820944274. PubMed ID: 32715976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
    Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
    BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathogenesis of disease progression in MLL-rearranged AML.
    Kotani S; Yoda A; Kon A; Kataoka K; Ochi Y; Shiozawa Y; Hirsch C; Takeda J; Ueno H; Yoshizato T; Yoshida K; Nakagawa MM; Nannya Y; Kakiuchi N; Yamauchi T; Aoki K; Shiraishi Y; Miyano S; Maeda T; Maciejewski JP; Takaori-Kondo A; Ogawa S; Makishima H
    Leukemia; 2019 Mar; 33(3):612-624. PubMed ID: 30209403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pan-cancer analysis identifies
    Chang QH; Mao T; Tao Y; Dong T; Tang XX; Ge GH; Xu ZJ
    Aging (Albany NY); 2021 Mar; 13(8):11096-11119. PubMed ID: 33744857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.
    Xiong C; Wang Z; Wang G; Zhang C; Jin S; Jiang G; Bai D
    Invest New Drugs; 2021 Oct; 39(5):1439-1453. PubMed ID: 33942202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.
    Li Y; Qi D; Zhu B; Ye X
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of genes that control core fucosylation in hepatocellular carcinoma: Systematic review.
    Norton PA; Mehta AS
    World J Gastroenterol; 2019 Jun; 25(23):2947-2960. PubMed ID: 31249452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High HBXIP expression is related to poor prognosis in HCC by extensive database interrogation.
    Guo ZY; Jiang LP; Zhu ZT
    Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6196-6207. PubMed ID: 34730200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
    Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
    Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases.
    Hou JY; Wu HY; He RQ; Lin P; Dang YW; Chen G
    Pathol Res Pract; 2019 Jan; 215(1):177-194. PubMed ID: 30473171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma.
    Mei J; Wang R; Xia D; Yang X; Zhou W; Wang H; Liu C
    DNA Cell Biol; 2020 Oct; 39(10):1838-1849. PubMed ID: 32876480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.